| Paul Salib, DO | |
|
1675 Leahy St Ste 315a, Muskegon, MI 49442-5543 | |
| (714) 553-3370 | |
| Not Available |
| Full Name | Paul Salib |
|---|---|
| Gender | Male |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 1675 Leahy St Ste 315a, Muskegon, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780119404 | NPI | - | NPPES |
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20191216001523 |
News Archive
With cold weather on the horizon, podiatrists at Temple University's School of Podiatric Medicine warn that people of all ages need to take precautions to protect their feet from cold-related injuries like frostbite, ankle sprains and fractures.
A class of anticancer drugs currently being evaluated in phase 3 clinical trials may also be an effective treatment for Hutchinson-Gilford progeria syndrome (HGPS), a fatal genetic disorder that causes premature aging.
Physicians should include screening for psychosocial comorbidities and obesity when evaluating children with lower urinary tract dysfunction, say researchers.
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
› Verified 8 days ago
| Entity Name | Afra Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912676198 PECOS PAC ID: 3476941493 Enrollment ID: O20211025002050 |
News Archive
With cold weather on the horizon, podiatrists at Temple University's School of Podiatric Medicine warn that people of all ages need to take precautions to protect their feet from cold-related injuries like frostbite, ankle sprains and fractures.
A class of anticancer drugs currently being evaluated in phase 3 clinical trials may also be an effective treatment for Hutchinson-Gilford progeria syndrome (HGPS), a fatal genetic disorder that causes premature aging.
Physicians should include screening for psychosocial comorbidities and obesity when evaluating children with lower urinary tract dysfunction, say researchers.
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Salib, DO 213 Highland Ave, Wayne, PA 19087-4745 Ph: (714) 553-3370 | Paul Salib, DO 1675 Leahy St Ste 315a, Muskegon, MI 49442-5543 Ph: (714) 553-3370 |
News Archive
With cold weather on the horizon, podiatrists at Temple University's School of Podiatric Medicine warn that people of all ages need to take precautions to protect their feet from cold-related injuries like frostbite, ankle sprains and fractures.
A class of anticancer drugs currently being evaluated in phase 3 clinical trials may also be an effective treatment for Hutchinson-Gilford progeria syndrome (HGPS), a fatal genetic disorder that causes premature aging.
Physicians should include screening for psychosocial comorbidities and obesity when evaluating children with lower urinary tract dysfunction, say researchers.
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
› Verified 8 days ago